A Phase 1/1b Study of ASP2074 in Participants With Metastatic or Locally Advanced Solid Tumors
Latest Information Update: 22 Nov 2024
At a glance
- Drugs ASP-2074 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma Global Development
Most Recent Events
- 18 Nov 2024 Status changed from active, no longer recruiting to discontinued.
- 26 Aug 2024 Planned End Date changed from 31 Dec 2027 to 31 Oct 2024.
- 26 Aug 2024 Planned primary completion date changed from 30 Sep 2027 to 31 Oct 2024.